Figure 2.

Patient disposition. ^aOne participant was found to have previously been exposed to 2 anti‐TNF biologic agents in the context of a previous clinical trial. The participant had already been dosed GSK2982772 and was therefore not withdrawn from the trial. ^bOne participant did not comply with contraception requirements. This was discovered on day 85, and the participant was therefore not withdrawn from the trial. ^cOne participant, randomized to the placebo group, erroneously received GSK2982772 on the day 29 visit. The participant was included in the 60‐mg b.i.d. treatment group. ^dOne participant was given captopril, a prohibited medication, for an SAE of hypertension on day 15 following a scheduled arthroscopic operation on the right knee. The participant was not withdrawn from the study as there were no safety concerns. ^eOne participant died following an accidental overdose of methylenedioxymethamphetamine 39 days after the start of the trial. ^fOne participant developed a herpes zoster infection on day 9 and was withdrawn from the study. AE, adverse event; b.i.d., twice daily; t.i.d., three times daily; SAE, serious adverse event.